Jump to content
Powered by

Baden-Württemberg to fund MediCyte research

MediCyte GmbH, based in the Heidelberg Technology Park, is among the winners of the Baden-Württemberg Ministry of Science, Research and the Arts’ biotechnology funding programme. MediCyte develops and markets products and services in the field of human cells.

MediCyte’s project focuses on the development of innovative cell culture systems for the cultivation of human liver cells (hepatocytes) which are important for research and development. It was previously thought impossible to grow hepatocytes in cell culture, but MediCyte has developed an innovative method to investigate the problem and develop solutions that will eventually allow the proliferation of hepatocytes in vitro. In addition, the company will also establish cell culture systems in which the hepatocytes regain certain properties, which they have when attached to the liver, but which they lose once removed from the organ.

Hepatocyte culture systems increase drug safety

The liver is the largest organ in the human body and plays a major role in the detoxification of harmful substances. It also plays a major role in the biological degradation of drugs. The cell culture systems which are currently available are only of limited use for predicting these degradation processes. The new hepatocyte culture systems might enable researchers to find drugs that have fewer side effects. The results gained in the new project have the potential to contribute to the quicker and cheaper development of drugs. They might also help reduce the number of animal experiments needed to test drugs, as in future, a larger number of cell culture tests will be available to perform tests currently carried out on animals.

MediCyte will invest almost €400,000 in this research project, part of which is funded through the Baden-Württemberg biotechnology funding programme.

“The results of our development broadens the applicability of cell systems in basic biomedical research, but also promotes the development of new active substances in the pharmaceutical and cosmetics industry,” explained Dr. Joris Braspenning, CSO of MediCyte GmbH.

“The new project also contributes to MediCyte’s sustainable development as a biotechnology SME, which also benefits Heidelberg and Baden-Württemberg,” adds Stefan Holder, CFO of MediCyte GmbH.

Source: Medicyte GmbH - 12.02.2008 (P)
Website address: https://www.gesundheitsindustrie-bw.de/en/article/news/baden-wuerttemberg-to-fund-medicyte-research